In breast cancer, aberrant expression of Sox2 is detected in up to 30% of the tumors detectable by immunohistochemistry [4], and this aberrancy correlates with larger tumor size, higher tumor grade [5], and lymph node metastasis [6]. Here, SOX2 is linked to breast cancer.